Annual report pursuant to Section 13 and 15(d)

Segments (Details)

v3.3.1.900
Segments (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Segment Reporting Information [Line Items]                      
Revenue from services                 $ 329,739 $ 8,666 $ 11,658
Product revenues                 80,146 76,983 68,161
Revenue from transfer of intellectual property and other                 81,853 5,476 16,711
Operating (loss) income                 (98,481) (145,815) (79,632)
Depreciation and amortization                 42,248 14,927 15,216
Net loss from investment in investees                 (7,105) (3,587) (11,456)
Revenues $ 276,191 $ 143,034 $ 42,429 $ 30,084 $ 25,533 $ 19,773 $ 23,545 $ 22,274 491,738 91,125 96,530
Assets [1] 2,799,614       1,267,664       2,799,614 1,267,664  
Goodwill 743,348 [1]       224,292 [1]       743,348 [1] 224,292 [1] 226,373
United States                      
Segment Reporting Information [Line Items]                      
Revenues                 344,464 14,142 28,369
Ireland                      
Segment Reporting Information [Line Items]                      
Revenues                 78,989 0 0
Chile                      
Segment Reporting Information [Line Items]                      
Revenues                 29,885 29,154 31,650
Spain                      
Segment Reporting Information [Line Items]                      
Revenues                 16,622 21,323 18,800
Israel                      
Segment Reporting Information [Line Items]                      
Revenues                 18,107 20,638 13,252
Mexico                      
Segment Reporting Information [Line Items]                      
Revenues                 3,671 5,807 4,459
Other                      
Segment Reporting Information [Line Items]                      
Revenues                 0 61 0
Corporate, Non-Segment                      
Segment Reporting Information [Line Items]                      
Revenue from services                 140 240 825
Revenue from transfer of intellectual property and other                 0 0 0
Operating (loss) income                 (46,512) (27,725) (24,473)
Depreciation and amortization                 85 97 149
Net loss from investment in investees                 0 0 0
Assets 61,762       95,094       61,762 95,094  
Goodwill 0       0       0 0  
Segment Reconciling Items                      
Segment Reporting Information [Line Items]                      
Operating (loss) income                 (1,280) (2,042) (3,151)
Pharmaceutical | Operating Segments                      
Segment Reporting Information [Line Items]                      
Revenue from services                 0 0 0
Product revenues                 80,146 76,983 68,161
Revenue from transfer of intellectual property and other                 81,853 5,285 15,160
Operating (loss) income                 (40,395) (94,401) (29,809)
Depreciation and amortization                 10,245 7,936 8,234
Net loss from investment in investees                 (7,105) (3,587) (11,456)
Assets 1,258,011       1,064,498       1,258,011 1,064,498  
Goodwill 251,225       173,327       251,225 173,327  
Diagnostics | Operating Segments                      
Segment Reporting Information [Line Items]                      
Revenue from services                 329,599 8,426 10,833
Revenue from transfer of intellectual property and other                 0 191 1,551
Operating (loss) income                 (10,294) (21,647) (22,199)
Depreciation and amortization                 31,918 6,894 6,833
Net loss from investment in investees                 0 0 $ 0
Assets 1,479,841       108,072       1,479,841 108,072  
Goodwill $ 492,123       $ 50,965       $ 492,123 $ 50,965  
[1] As of December 31, 2014, total assets include $7.6 million and total liabilities include $12.1 million related to SciVac Ltd (“SciVac”). SciVac was a consolidated variable interest entity which we deconsolidated in July 2015. Refer to Note 4. SciVac’s consolidated assets were owned by SciVac and SciVac’s consolidated liabilities had no recourse against us.